Find Osimertinib Mesylate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1421373-66-1, Azd-9291 mesylate, Azd9291 mesylate, Azd-9291 (mesylate), Mereletinib mesylate, Tagrisso
Molecular Formula
C29H37N7O5S
Molecular Weight
595.7  g/mol
InChI Key
FUKSNUHSJBTCFJ-UHFFFAOYSA-N
FDA UNII
RDL94R2A16

Osimertinib Mesylate
Osimertinib Mesylate is the mesylate salt form of osimertinib, a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.
1 2D Structure

Osimertinib Mesylate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;methanesulfonic acid
2.1.2 InChI
InChI=1S/C28H33N7O2.CH4O3S/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24;1-5(2,3)4/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32);1H3,(H,2,3,4)
2.1.3 InChI Key
FUKSNUHSJBTCFJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O
2.2 Other Identifiers
2.2.1 UNII
RDL94R2A16
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Azd-9291

2. Azd-9291 Mesylate

3. Azd9291

4. Azd9291 Mesylate

5. Mereletinib

6. Mereletinib Mesilate

7. Mereletinib Mesylate

8. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide

9. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide Methanesulfonate (1:1)

10. Osimertinib

11. Osimertinib Mesilate

12. Tagrisso

2.3.2 Depositor-Supplied Synonyms

1. 1421373-66-1

2. Azd-9291 Mesylate

3. Azd9291 Mesylate

4. Azd-9291 (mesylate)

5. Mereletinib Mesylate

6. Tagrisso

7. Osimertinib Mesilate

8. Mereletinib Mesilate

9. Osimertinib Mesylate [usan]

10. Rdl94r2a16

11. N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;methanesulfonic Acid

12. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide Methanesulfonate

13. Osimertinib Mesilate (jan)

14. Osimertinib Mesylate (usan)

15. 2-propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, Methanesulfonate (1:1)

16. Osimertinib Mesilate [jan]

17. 2-propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-, Compd. With Methanesulfonate (1:2)

18. Unii-rdl94r2a16

19. Tagrisso (tn)

20. Osimertinib Monomesylate

21. Azd 9291 Mesylate

22. Osimertinib Methanesulfonate

23. Amy226

24. Chembl3545063

25. Schembl14661152

26. Chebi:90948

27. Osimertinib Mesylate [mi]

28. Dtxsid101027822

29. Bcp09934

30. Ex-a1577

31. Hy-15772a

32. Mfcd28137994

33. Osimertinib Mesilate [who-dd]

34. Akos026673944

35. Ds-9913

36. Sb22953

37. Ac-29022

38. Da-35303

39. Osimertinib Mesylate [orange Book]

40. Azd-9291 Mesylate (osimertinibmereletinib)

41. Ft-0699962

42. S5078

43. D10766

44. Q27162942

45. Azd9291 Ms Salt, Osimertinib Ms Salt; Mereletinib Ms Salt

46. N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide Methanesulfonate

47. N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide Methanesulfonate

2.3.3 Other Synonyms

1. Osimertinib

2.4 Create Date
2014-10-10
3 Chemical and Physical Properties
Molecular Weight 595.7 g/mol
Molecular Formula C29H37N7O5S
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count10
Rotatable Bond Count10
Exact Mass595.25768848 g/mol
Monoisotopic Mass595.25768848 g/mol
Topological Polar Surface Area150 Ų
Heavy Atom Count42
Formal Charge0
Complexity845
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

TAGRISSO as monotherapy is indicated for:

-the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations

- the first-line treatment of adult patients NSCLC with activating EGFR mutations.

- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

TAGRISSO as monotherapy is indicated for:

- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.

- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


5.2 ATC Code

L01XE


Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Osimertinib

About the Company : Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its produc...

Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its products under Egis’ brand names in 18 countries. In total, the company’s APIs & finished products reach 100 countries. Egis’ focus lies on treating diseases of cardiovascular & central nervous systems; however, it also provides modern treatment solutions in the fields of diabetology, dermatology & wound care. Our research and development activities focus on high-quality, value-added branded generic products. From 2023, Egis offers its CDMO & CMO services as well.
Egis Pharmaceuticals

02

Fermion Oy

Finland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

Flag Finland
Digital Content Digital Content

Osimertinib

About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & F...

Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
fermion

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFaran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.

Flag Iran
Digital Content Digital Content

Osimertinib Mesylate

About the Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs)...

Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs) and finished dosage forms. For the past three years, the company focused on extracting alkaloid opiates, controlled substances, and narcotics. The APIs are widely used by major pharmaceutical companies nationwide and exported to the Middle East. All production adheres to local GMP standards in an SOP-driven environment with modern systems and utilities, ensuring the highest quality and safety.
Faran Shimi Pharmaceutical

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

Flag India
Digital Content Digital Content

Osimertinib

About the Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cyto...

Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cytotoxic & oncology products. It has 2 R&D centers & 3 cGMP plants successfully audited by the USFDA, EUGMP, EDQM, KFDA & COFEPRIS. It offers CDMO services for generic APIs & NCEs, intermediates & key building blocks.Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Aarti Industries Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content

Osimertinib Mesylate

About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...

Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development Zone, Shandong Province, Shandong Loncom has operational API pilot tests and production bases adhering to international standards. With 13 production lines dedicated to oral solid preparations, oral liquid preparations and API, it is actively expanding its preparation workshops for small-volume injections, soft capsules, eye drops, topical medicines and innovative drug R&D centres.
Shandong Loncom Pharmaceutical company banner

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Osimertinib Mesylate

About the Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...

​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry.
Shanghai Minbiotech CB

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Osimertinib Mesylate

About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry with over 350 Products portfolio. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.
TAPI Company Banner

08

APS Symposium
Not Confirmed
arrow
arrow
APS Symposium
Not Confirmed

Osimertinib Mesylate

About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.
blank

09

APS Symposium
Not Confirmed
arrow
arrow
APS Symposium
Not Confirmed

Osimertinib

About the Company : Baran Chemical and Pharmaceutical Company operates as part of the DAKPHA Holding conglomerate. This conglomerate, driven by dedicated experts and state-of-the-art technology, is de...

Baran Chemical and Pharmaceutical Company operates as part of the DAKPHA Holding conglomerate. This conglomerate, driven by dedicated experts and state-of-the-art technology, is dedicated to advancing the pharmaceutical raw materials sector, producing diverse medical formulations, and enhancing public health by fulfilling community needs. Among its affiliated companies are "Danesh Pharmaceutical Development" and "Alborz Pharmed".
blank

10

APS Symposium
Not Confirmed
arrow
arrow
APS Symposium
Not Confirmed

AZD-9291 mesylate

About the Company : Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical interm...

Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical intermediates and new drugs. The company is mainly engaged in customized synthesis of complex small molecule frameworks and pharmaceutical intermediates, and independent R&D of innovative new drugs; and provides services of production technology improvement and consigned new drug development for pharmaceutical enterprises. Haoyuan Chemexpress is committed to researching and developing APIs and pharmaceutical intermediates with high synthesis technology barriers and difficulties and high added value, and also focuses on the synthesis of chiral compounds.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655663400,"product":"OSIMERTINIB MESYLATE, B.NO.OMT52201, MFG","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"22000","totalValueFC":"10895.3","currency":"USD","unitRateINR":1700000,"date":"20-Jun-2022","totalValueINR":"850000","totalValueInUsd":"10895.3","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"2243029","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1668018600,"product":"OSIMERTINIB MESYLATE, B.NO.2204005231, M","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"22000","totalValueFC":"33193.4","currency":"USD","unitRateINR":1806000,"date":"10-Nov-2022","totalValueINR":"2709000","totalValueInUsd":"33193.4","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"5364234","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1685557800,"product":"OSIMERTINIB MESYLATE, B.NO. 2204005231,","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"22000","totalValueFC":"87303.2","currency":"USD","unitRateINR":1794000.0487500001,"date":"01-Jun-2023","totalValueINR":"7176000.195","totalValueInUsd":"87303.2","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"0","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689791400,"product":"OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER","customerCountry":"TURKEY","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"25000","totalValueFC":"12276.5","currency":"USD","unitRateINR":2017999.6200000001,"date":"20-Jul-2023","totalValueINR":"1008999.81","totalValueInUsd":"12276.5","indian_port":"AHMEDABAD AIR","hs_no":"29335990","bill_no":"0","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1704825000,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)(PHARMACEUTICALS RAW MATERIAL) PRODUCTOSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER OF","customerCountry":"TURKEY","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"7000","totalValueFC":"1714.6","currency":"USD","unitRateINR":570009,"date":"10-Jan-2024","totalValueINR":"142502.25","totalValueInUsd":"1714.6","indian_port":"Ahmedabad Air","hs_no":"29335990","bill_no":"6662074","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1704997800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS - (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) PRODUCT - OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO -","customer":"TO","customerCountry":"URUGUAY","quantity":"0.40","actualQuantity":"0.4","unit":"KGS","unitRateFc":"22000","totalValueFC":"8371.1","currency":"USD","unitRateINR":1739344.125,"date":"12-Jan-2024","totalValueINR":"695737.65","totalValueInUsd":"8371.1","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"6705898","productDescription":"API","marketType":"","country":"URUGAY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705429800,"product":"RAW MATERIAL FOR USE IN PHARMACEUTICAL INDUSTRY : OSIMERTINIB MESYLATE IHS","address":"A 401 NEELKANTH AVENUE,OPP SEEMA H","city":"AHMEDABAD,GUJARAT","supplier":"GONANE PHARMA","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"HSBC BANK","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"13000","totalValueFC":"2368.4","currency":"USD","unitRateINR":984225.05000000005,"date":"17-Jan-2024","totalValueINR":"196845.01","totalValueInUsd":"2368.4","indian_port":"Ahmedabad Air","hs_no":"29242190","bill_no":"6808026","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"A 401 NEELKANTH AVENUE,OPP SEEMA H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705861800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS -(API) (PHARMACEUTICALS RAW MATERIAL FOR PHARMA)PRODUCT- OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"BUDAPEST,","customer":"TO THE ORDER OF","customerCountry":"HUNGARY","quantity":"5.50","actualQuantity":"5.5","unit":"KGS","unitRateFc":"10000","totalValueFC":"54363.8","currency":"USD","unitRateINR":821502.78727272723,"date":"22-Jan-2024","totalValueINR":"4518265.33","totalValueInUsd":"54363.8","indian_port":"Ahmedabad Air","hs_no":"29335990","bill_no":"6937264","productDescription":"API","marketType":"REGULATED MARKET","country":"HUNGARY","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1723746600,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER OF","customerCountry":"TURKEY","quantity":"0.56","actualQuantity":"0.555","unit":"KGS","unitRateFc":"7000","totalValueFC":"3718.9","currency":"USD","unitRateINR":562047.98198198189,"date":"16-Aug-2024","totalValueINR":"311936.63","totalValueInUsd":"3718.9","indian_port":"Ahmedabad Air","hs_no":"29335990","bill_no":"3256323","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1724956200,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS ? (API) (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) ? OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"REYKJAVIK KEFLAVIK","customer":"TO THE ORDER OF.","customerCountry":"ICELAND","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"10000","totalValueFC":"1971.2","currency":"USD","unitRateINR":826720.34999999998,"date":"30-Aug-2024","totalValueINR":"165344.07","totalValueInUsd":"1971.2","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"3599819","productDescription":"API","marketType":"REGULATED MARKET","country":"ICELAND","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726079400,"product":"OSIMERTINIB MESYLATE IH ROW","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO LABS LIMITED","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"EASTERN BANK PLC","customerCountry":"BANGLADESH","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"45000","totalValueFC":"11134.5","currency":"USD","unitRateINR":3732350,"date":"12-Sep-2024","totalValueINR":"933087.5","totalValueInUsd":"11134.5","indian_port":"Hyderabad Air","hs_no":"29242190","bill_no":"3943519","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726079400,"product":"OSIMERTINIB MESYLATE IH","address":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA","city":"N\/A","supplier":"VANNSH LIFE SCIENCES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"SAMDRUP-JONKHAR","customer":"AZISTA BHUTAN HEALTHCARE LTD","customerCountry":"BHUTAN","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"300000","totalValueFC":"35799","currency":"INR","unitRateINR":300000,"date":"12-Sep-2024","totalValueINR":"3000000","totalValueInUsd":"35799","indian_port":"Darranga","hs_no":"29339990","bill_no":"3954245","productDescription":"API","marketType":"","country":"BHUTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Darranga","supplierAddress":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA, N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726684200,"product":"OSIMERTINIB MESYLATE IH","address":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA","city":"N\/A","supplier":"VANNSH LIFE SCIENCES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"SAMDRUP-JONKHAR","customer":"AZISTA BHUTAN HEALTHCARE LTD","customerCountry":"BHUTAN","quantity":"3.60","actualQuantity":"3.6","unit":"KGS","unitRateFc":"300000","totalValueFC":"12887.6","currency":"INR","unitRateINR":300000,"date":"19-Sep-2024","totalValueINR":"1080000","totalValueInUsd":"12887.6","indian_port":"Darranga","hs_no":"29339990","bill_no":"4151419","productDescription":"API","marketType":"","country":"BHUTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Darranga","supplierAddress":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA, N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1739298600,"product":"OSIMERTINIB MESYLATE IH","address":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA","city":"N\/A","supplier":"VANNSH LIFE SCIENCES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"SAMDRUP-JONKHAR","customer":"AZISTA BHUTAN HEALTHCARE LTD","customerCountry":"BHUTAN","quantity":"7.21","actualQuantity":"7.205","unit":"KGS","unitRateFc":"400000","totalValueFC":"33140.1","currency":"INR","unitRateINR":400000,"date":"12-Feb-2025","totalValueINR":"2882000","totalValueInUsd":"33140.1","indian_port":"Darranga","hs_no":"29339990","bill_no":"8095736","productDescription":"API","marketType":"","country":"BHUTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Darranga","supplierAddress":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA, N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1740767400,"product":"OSIMERTINIB MESYLATE IH US","address":"HETERO CORPORATE, NO. 7-2-A2,,INDU","city":"HYDERABAD,TELANGANA","supplier":"HETERO LABS LIMITED","supplierCountry":"INDIA","foreign_port":"MONTREAL, QC","customer":"PHARMASCIENCE INC","customerCountry":"CANADA","quantity":"7.00","actualQuantity":"7","unit":"KGS","unitRateFc":"7000","totalValueFC":"48451.7","currency":"USD","unitRateINR":599538.6471428572,"date":"01-Mar-2025","totalValueINR":"4196770.53","totalValueInUsd":"48451.7","indian_port":"Hyderabad Air","hs_no":"29242190","bill_no":"8620909","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,,INDU, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1745260200,"product":"ACTIVE PHARMACEUTICAL INGREDIENTS(API)(PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES)PRODUCT- OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"BAGDAD, METROPOLITAN","customer":"TO THE ORDER OF","customerCountry":"IRAQ","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"40000","totalValueFC":"19653.6","currency":"USD","unitRateINR":3364765.1000000001,"date":"22-Apr-2025","totalValueINR":"1682382.55","totalValueInUsd":"19653.6","indian_port":"Ahmedabad Air","hs_no":"29420090","bill_no":"1158910","productDescription":"API","marketType":"","country":"IRAQ","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1745260200,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS(API)(PHARMACEUTICALS RAW MATERIAL FOR PHARMAINDUSTRIES) PRODUCT-OSIMERTINIB MESYLATE","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"BAGDAD, METROPOLITAN","customer":"TO THE ORDER OF","customerCountry":"IRAQ","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"40000","totalValueFC":"19653.6","currency":"USD","unitRateINR":3364765.1000000001,"date":"22-Apr-2025","totalValueINR":"1682382.55","totalValueInUsd":"19653.6","indian_port":"Ahmedabad Air","hs_no":"29420090","bill_no":"1157261","productDescription":"API","marketType":"","country":"IRAQ","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""}]
20-Jun-2022
22-Apr-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

FDA Orange Book

read-more
read-more

01

ASTRAZENECA

United Kingdom
APS Symposium
Not Confirmed
arrow

ASTRAZENECA

United Kingdom
arrow
APS Symposium
Not Confirmed

OSIMERTINIB MESYLATE

Brand Name : TAGRISSO

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 40MG BASE

Approval Date : 2015-11-13

Application Number : 208065

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

02

ASTRAZENECA

United Kingdom
APS Symposium
Not Confirmed
arrow

ASTRAZENECA

United Kingdom
arrow
APS Symposium
Not Confirmed

OSIMERTINIB MESYLATE

Brand Name : TAGRISSO

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 80MG BASE

Approval Date : 2015-11-13

Application Number : 208065

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

03

APS Symposium
Not Confirmed
arrow
arrow
APS Symposium
Not Confirmed

OSIMERTINIB MESYLATE

Brand Name : OSIMERTINIB MESYLATE

Dosage Form : TABLET;ORAL

Dosage Strength : 40MG

Approval Date :

Application Number : 214263

RX/OTC/DISCN :

RLD :

TE Code :

blank

04

APS Symposium
Not Confirmed
arrow
arrow
APS Symposium
Not Confirmed

OSIMERTINIB MESYLATE

Brand Name : OSIMERTINIB MESYLATE

Dosage Form : TABLET;ORAL

Dosage Strength : 80MG

Approval Date :

Application Number : 214263

RX/OTC/DISCN :

RLD :

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Regulatory Info :

Registration Country : Hungary

Osimertinib Mesylate

Brand Name :

Dosage Form : Tablet

Dosage Strength : 40MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Hungary

Egis Pharmaceuticals

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Regulatory Info :

Registration Country : Hungary

Osimertinib Mesylate

Brand Name :

Dosage Form : Tablet

Dosage Strength : 80MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Hungary

Egis Pharmaceuticals

03

AstraZeneca AB

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca AB

United Kingdom
arrow
APS Symposium
Not Confirmed

osimertinibmesilat

Brand Name : TAGRISSO

Dosage Form : FILM COATED PILL

Dosage Strength : 80 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

04

AstraZeneca AB

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca AB

United Kingdom
arrow
APS Symposium
Not Confirmed

osimertinibmesilat

Brand Name : TAGRISSO

Dosage Form : FILM COATED PILL

Dosage Strength : 40 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

05

AstraZeneca AB (2)

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca AB (2)

United Kingdom
arrow
APS Symposium
Not Confirmed

AZD-9291 mesylate

Brand Name : Tagrisso

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 40 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

06

AstraZeneca AB (2)

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca AB (2)

United Kingdom
arrow
APS Symposium
Not Confirmed

AZD-9291 mesylate

Brand Name : Tagrisso

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 80 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

07

AstraZeneca AG

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca AG

United Kingdom
arrow
APS Symposium
Not Confirmed

Osimertinibum

Brand Name : Tagrisso

Dosage Form : Tabl

Dosage Strength : 40mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

08

AstraZeneca AG

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca AG

United Kingdom
arrow
APS Symposium
Not Confirmed

Osimertinibum

Brand Name : Tagrisso

Dosage Form : Tabl

Dosage Strength : 80mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

read-more
read-more

01

ASTRAZENECA CANADA INC

United Kingdom
DIA 2025
Not Confirmed
arrow

ASTRAZENECA CANADA INC

United Kingdom
arrow
DIA 2025
Not Confirmed

OSIMERTINIB (OSIMERTINIB MESYLATE)

Brand Name : TAGRISSO

Dosage Form : TABLET

Dosage Strength : 80MG

Packaging : 30

Approval Date :

Application Number : 2456222

Regulatory Info : Prescription

Registration Country : Canada

blank

02

ASTRAZENECA CANADA INC

United Kingdom
DIA 2025
Not Confirmed
arrow

ASTRAZENECA CANADA INC

United Kingdom
arrow
DIA 2025
Not Confirmed

OSIMERTINIB (OSIMERTINIB MESYLATE)

Brand Name : TAGRISSO

Dosage Form : TABLET

Dosage Strength : 40MG

Packaging : 30

Approval Date :

Application Number : 2456214

Regulatory Info : Prescription

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Australia

read-more
read-more

01

AstraZeneca Pty Ltd

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
APS Symposium
Not Confirmed

Osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

02

AstraZeneca Pty Ltd

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
APS Symposium
Not Confirmed

Osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

03

AstraZeneca Pty Ltd

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
APS Symposium
Not Confirmed

Osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

04

AstraZeneca Pty Ltd

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
APS Symposium
Not Confirmed

Osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

05

AstraZeneca Pty Ltd

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
APS Symposium
Not Confirmed

Osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

06

AstraZeneca Pty Ltd

United Kingdom
APS Symposium
Not Confirmed
arrow

AstraZeneca Pty Ltd

United Kingdom
arrow
APS Symposium
Not Confirmed

Osimertinib

Brand Name : Tagrisso

Dosage Form :

Dosage Strength :

Packaging : 30

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Osimertinib Mesylate

Brand Name : Mertisso

Dosage Form : Film Coated Tablet

Dosage Strength : 40MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

01

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Packaging :

Regulatory Info :

Osimertinib Mesylate

Dosage : Film Coated Tablet

Dosage Strength : 40MG

Brand Name : Mertisso

Approval Date :

Application Number :

Registration Country : Iran

NanoAlvand

02

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Osimertinib Mesylate

Brand Name : Mertisso

Dosage Form : Film Coated Tablet

Dosage Strength : 80MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

02

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Packaging :

Regulatory Info :

Osimertinib Mesylate

Dosage : Film Coated Tablet

Dosage Strength : 80MG

Brand Name : Mertisso

Approval Date :

Application Number :

Registration Country : Iran

NanoAlvand

03

Pluviaendo

Turkey
APS Symposium
Not Confirmed
arrow

Pluviaendo

Turkey
arrow
APS Symposium
Not Confirmed

Osimertinib Mesylate

Brand Name :

Dosage Form : Tablet

Dosage Strength : 40MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Turkey

blank

03

Pluviaendo

Turkey
APS Symposium
Not Confirmed
arrow

Pluviaendo

Turkey
arrow
APS Symposium
Not Confirmed

Osimertinib Mesylate

Dosage : Tablet

Dosage Strength : 40MG

Brand Name :

Approval Date :

Application Number :

Registration Country : Turkey

blank

04

Pluviaendo

Turkey
APS Symposium
Not Confirmed
arrow

Pluviaendo

Turkey
arrow
APS Symposium
Not Confirmed

Osimertinib Mesylate

Brand Name :

Dosage Form : Tablet

Dosage Strength : 80MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Turkey

blank

04

Pluviaendo

Turkey
APS Symposium
Not Confirmed
arrow

Pluviaendo

Turkey
arrow
APS Symposium
Not Confirmed

Osimertinib Mesylate

Dosage : Tablet

Dosage Strength : 80MG

Brand Name :

Approval Date :

Application Number :

Registration Country : Turkey

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

STOCK RECAP #PipelineProspector

read-more
read-more
Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD
Pharma indices settled slightly lower in September after four months of solid gains. The three major pharma indices dropped about 2 percent each. The Nasdaq Biotechnology Index (NBI) closed at 4,767.84, down from 4,870.17, the SPDR S&P Biotech ETF (XBI) dropped to 98.8 from 101.1, and the S&P Biotechnology Select Industry Index (SPSIBI) fell to 7,707.36 from 7,897.9. Despite these declines, September was a dynamic month for the pharmaceutical industry, marked by significant regulatory approvals.September saw notable developments in the field of chronic obstructive pulmonary disease (COPD). After over a decade, COPD saw two significant approvals. The US Food and Drug Administration (FDA) expanded the label of Regeneron and Sanofi’s mega-blockbuster drug, Dupixent, to include the treatment of COPD. Already a game-changer in treating conditions like asthma and atopic dermatitis, Dupixent became the first-ever biologic medicine for COPD patients in the US.Additionally, GSK’s asthma drug Nucala scored a vital win in a late-stage study for treating COPD. The British drugmaker reported that the monoclonal antibody significantly and meaningfully reduced the annualized rate of moderate to severe exacerbations of what is the world’s third leading cause of death. These developments come on the heels of FDA’s approval of Verona’s Ohtuvayre in June. Ohtuvayre has a novel mechanism of action for the maintenance treatment of COPD. Access the Pipeline Prospector Dashboard for September 2024 Newsmakers (Free Excel)BMS’ Karuna bet pays off with schizo drug approval; FDA okays Astra’s nasal spray flu shotIn what was one of the most closely watched decisions this year, BMS’ KarXT won a landmark FDA approval for treating schizophrenia. Branded Cobenfy, the drug is the first antipsychotic that targets cholinergic receptors. Ever since the 1950s, when antipsychotics began being used to treat schizophrenia, they have worked by blocking a dopamine receptor. But those have been associated with serious side effects like weight gain, high rates of cardiac disease, early death and patients complaining about feeling sluggish and unmotivated. Cobenfy’s new approach has experts excited, and its peak sales are expected to come in at US$ 7.5 billion a year, validating BMS’ US$ 14 billion acquisition of Karuna Therapeutics. BMS’ stock gained 2 percent.That wasn’t the only landmark move. FDA approved two treatments for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disorder. Zevra Therapeutics’ Miplyffa became the first-ever treatment approved for NPC, addressing a critical unmet need for patients who, on average, only live about 13 years. Soon after Miplyffa’s approval, IntraBio’s Aqneursa was also granted approval by the FDA. Designed to alleviate neurological symptoms in both adults and children weighing at least 15 kilograms, Aqneursa stands out as the only FDA-approved stand-alone therapy for NPC.Just in time for winter, AstraZeneca’s first self-administered flu vaccine — FluMist — also bagged FDA approval last month. This nasal spray vaccine can be used at home, potentially increasing vaccination rates among needle-averse individuals. Access the Pipeline Prospector Dashboard for September 2024 Newsmakers (Free Excel) Astra’s Tagrisso okayed for inoperable lung cancer; UCB Bimzelx bags 3 new approvalsMonths after AstraZeneca’s Tagrisso posted impressive phase 3 results, the drug received FDA approval for treating inoperable, stage 3 epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This makes Astra’s blockbuster the first targeted therapy for the indication.UCB’s Bimzelx secured three new FDA approvals for treating adults with active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. With a novel approach to treating these chronic inflammatory diseases, the company expects Bimzelx to significantly bolster sales, with peak sales of the med projected at € 4 billion (US$ 4.4 billion) or more.Eli Lilly’s Ebglyss was approved for moderate-to-severe eczema in patients who are unable to control symptoms with topical or other systemic treatments. Notably, Ebglyss offers a more convenient once-monthly dosing compared to twice-monthly for competitors, a feature that analysts note as attractive to both experts and patients. Access the Pipeline Prospector Dashboard for September 2024 Newsmakers (Free Excel)Astra-Daiichi’s ADC suffers double whammy; Intercept’s Ocaliva faces setbackThe month also brought its share of challenges. AstraZeneca (stock down 10 percent) and Daiichi Sankyo’s (stock down 23 percent) investigational antibody-drug conjugate (ADC) datopotamab deruxtecan suffered a double blow in late-stage trials. It first failed to significantly outperform the standard-of-care chemotherapy — docetaxel — in treating NSCLC. And then it failed to show notable improvement in overall survival compared to chemotherapy in breast cancer.Analysts had expected datopotamab deruxtecan to potentially become one of Astra’s best-selling drugs. The British-Swedish drugmaker had paid Daiichi US$ 1 billion upfront and promised an additional US$ 5 billion in milestone payments.Intercept Pharmaceuticals faced a major setback as FDA’s advisory committee voted against the confirmatory data for Ocaliva, which was granted accelerated approval in 2016 for primary biliary cholangitis.Vanda Pharmaceuticals hit back at FDA after the agency issued it a Complete Response Letter, declining to approve its drug — tradipitant — to treat gastroparesis. The company expressed deep frustration, highlighting the urgent need for new treatments. Access the Pipeline Prospector Dashboard for September 2024 Newsmakers (Free Excel)GSK’s asthma drug halves attacks; Abbvie’s Parkinson’s med meets all endpointsAmong late-stage wins, GSK’s new long-acting asthma drug, depemokimab, reduced asthma exacerbations by 54 percent and achieved a 72 percent reduction in exacerbations that required hospitalization or an ER visit. GSK is counting depemokimab among one of its 12 blockbuster launches and expects it to generate £ 3 billion (US$ 3.9 billion) in annual peak-sales.Similarly, Abbvie’s tavapadon, which was the subject of its US$ 8.7 billion buyout of Cerevel Therapeutics, met its primary and secondary endpoints in patients with early Parkinson's disease. Akeso and Summit Therapeutics’ experimental drug ivonescimab beat the world’s best-selling drug Keytruda hands down in a late-stage NSCLC trial. Ivonescimab reduced the risk of disease progression or death by 49 percent compared to Keytruda. Akeso and Summit’s stock jumped 40 percent and 69 percent, respectively.And, Ascendis Pharma announced topline data from a pivotal trial on TransCon CNP, a therapy to treat achondroplasia, a common form of dwarfism. TransCon CNP demonstrated a statistically significant annualized growth velocity of 5.89 cm/year in children treated, compared to 4.41 cm/year in the placebo group. Access the Pipeline Prospector Dashboard for September 2024 Newsmakers (Free Excel) Our viewWhile September didn’t witness a mega-deal, it did see groundbreaking advancements being signed off by the FDA. We have seen enough ups and downs in the pharma indices this year. Let’s hope the final quarter of the year ends on a strong note, both in terms of drug approvals and indices. Access the Pipeline Prospector Dashboard for September 2024 Newsmakers (Free Excel)

Impressions: 2537

https://www.pharmacompass.com/pipeline-prospector-blog/pipeline-prospector-sept-2024-bms-wins-landmark-fda-approval-for-schizophrenia-med-sanofi-s-dupixent-okayed-for-copd

#PharmaFlow by PHARMACOMPASS
03 Oct 2024

NEWS #PharmaBuzz

read-more
read-more

https://www.expresspharma.in/astrazeneca-india-gets-cdsco-approval-for-additional-indication-for-osimertinib-in-unresectable-egfr-mutated-lung-cancer/

EXPRESSPHARMA
29 May 2025

https://www.prnewswire.com/news-releases/major-cost-savings-on-top-cancer-drugs-with-india-approved-alternatives-302424081.html

PR NEWSWIRE
09 Apr 2025

https://www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-outperforms-osimertinib-with-a-significant-and-unprecedented-overall-survival-benefit-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-302412036.html

PR NEWSWIRE
27 Mar 2025

https://www.businesswire.com/news/home/20250325308922/en/New-study-results-reinforce-TAGRISSO-osimertinib-as-the-backbone-therapy-for-EGFR-mutated-lung-cancer-across-stages-and-settings

BUSINESSWIRE
25 Mar 2025

https://www.fiercepharma.com/pharma/after-key-win-over-astrazenecas-tagrisso-jj-touts-rybrevant-lazcluze-combo-new-standard-care

FIERCE PHARMA
08 Jan 2025

https://www.globenewswire.com/news-release/2025/01/02/3003295/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-for-ORPATHYS-and-TAGRISSO-Combination-in-Lung-Cancer-Patients-with-MET-amplification-After-Progression-on-Fir.html

GLOBENEWSWIRE
01 Jan 2025

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
ACS GCI
Not Confirmed
arrow
ACS GCI
Not Confirmed

Company :

Osimertinib Mesylate

Drug Cost (USD) : 1,081,280,466

Year : 2022

Prescribers : 8629

Prescriptions : 64678

blank

02

arrow
ACS GCI
Not Confirmed
arrow
ACS GCI
Not Confirmed

Company :

Osimertinib Mesylate

Drug Cost (USD) : 913,265,970

Year : 2021

Prescribers : 7780

Prescriptions : 56038

blank

03

arrow
ACS GCI
Not Confirmed
arrow
ACS GCI
Not Confirmed

Company :

Osimertinib Mesylate

Drug Cost (USD) : 793,479,172

Year : 2020

Prescribers : 7016

Prescriptions : 49761

blank

04

arrow
ACS GCI
Not Confirmed
arrow
ACS GCI
Not Confirmed

Company :

Osimertinib Mesylate

Drug Cost (USD) : 640,665,670

Year : 2019

Prescribers : 6471

Prescriptions : 41212

blank

05

arrow
ACS GCI
Not Confirmed
arrow
ACS GCI
Not Confirmed

Company :

Osimertinib Mesylate

Drug Cost (USD) : 387,940,690

Year : 2018

Prescribers : 4586

Prescriptions : 25308

blank

06

arrow
ACS GCI
Not Confirmed
arrow
ACS GCI
Not Confirmed

Company :

Osimertinib Mesylate

Drug Cost (USD) : 189,639,073

Year : 2017

Prescribers : 2321

Prescriptions : 12787

blank

07

arrow
ACS GCI
Not Confirmed
arrow
ACS GCI
Not Confirmed

Company :

Osimertinib Mesylate

Drug Cost (USD) : 125,850,146

Year : 2016

Prescribers : 1559

Prescriptions : 9143

blank

08

arrow
ACS GCI
Not Confirmed
arrow
ACS GCI
Not Confirmed

Company :

Osimertinib Mesylate

Drug Cost (USD) : 4,670,268

Year : 2015

Prescribers : 263

Prescriptions : 351

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Regulatory FDF Prices

read-more
read-more

01

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib Mesylate

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 40 mg

Price Per Pack (Euro) : 7,767.21

Published in :

Country : Norway

RX/OTC/DISCN :

blank

02

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib Mesylate

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 80 mg

Price Per Pack (Euro) : 7,767.21

Published in :

Country : Norway

RX/OTC/DISCN :

blank

03

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib Mesylate

Dosage Form : Tabl

Dosage Strength : 40mg

Price Per Pack (Euro) : 5192.59

Published in :

Country : Switzerland

RX/OTC/DISCN : Class A

blank

04

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib Mesylate

Dosage Form : Tabl

Dosage Strength : 80mg

Price Per Pack (Euro) : 5192.59

Published in :

Country : Switzerland

RX/OTC/DISCN : Class A

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Tagrisso

Osimertinib

arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 4,328

2019 Revenue in Millions : 3,189

Growth (%) : 36

blank

02

Brand Name : Tagrisso

Osimertinib

arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 5,015

2020 Revenue in Millions : 4,328

Growth (%) : 16

blank

03

Brand Name : Tagrisso

Osimertinib

arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 5,444

2021 Revenue in Millions : 5,015

Growth (%) : 9

blank

04

Brand Name : Tagrisso

Osimertinib

arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 5,799

2022 Revenue in Millions : 5,444

Growth (%) : 7

blank

05

Brand Name : Tagrisso

Osimertinib

arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 6,580

2023 Revenue in Millions : 5,799

Growth (%) : 13

blank

06

Brand Name : Tagrisso

Osimertinib Mesylate

arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 0

2014 Revenue in Millions : 19

Growth (%) : New Launch

blank

07

Brand Name : Tagrisso

Osimertinib Mesylate

arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 955

2016 Revenue in Millions : 423

Growth (%) : 126

blank

08

Brand Name : Tagrisso

Osimertinib Mesylate

arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 1,860

2017 Revenue in Millions : 955

Growth (%) : 95%

blank

09

Brand Name : Tagrisso

Osimertinib Mesylate

arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 423

2015 Revenue in Millions : 19

Growth (%) : 2,126

blank

10

Brand Name : Tagrisso

Osimertinib

arrow
ACS GCI
Not Confirmed

Brand Name : Tagrisso

United Kingdom
arrow
ACS GCI
Not Confirmed

Osimertinib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 3,189

2018 Revenue in Millions : 1,860

Growth (%) : 71

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1421373-66-1 / Osimertinib Mesylate API manufacturers, exporters & distributors?

Osimertinib Mesylate manufacturers, exporters & distributors 1

92

PharmaCompass offers a list of Osimertinib Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Osimertinib Mesylate manufacturer or Osimertinib Mesylate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Osimertinib Mesylate manufacturer or Osimertinib Mesylate supplier.

PharmaCompass also assists you with knowing the Osimertinib Mesylate API Price utilized in the formulation of products. Osimertinib Mesylate API Price is not always fixed or binding as the Osimertinib Mesylate Price is obtained through a variety of data sources. The Osimertinib Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Osimertinib Mesylate

Synonyms

1421373-66-1, Azd-9291 mesylate, Azd9291 mesylate, Azd-9291 (mesylate), Mereletinib mesylate, Tagrisso

Cas Number

1421373-66-1

Unique Ingredient Identifier (UNII)

RDL94R2A16

About Osimertinib Mesylate

Osimertinib Mesylate is the mesylate salt form of osimertinib, a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.

TAGRISSO Manufacturers

A TAGRISSO manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of TAGRISSO, including repackagers and relabelers. The FDA regulates TAGRISSO manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. TAGRISSO API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of TAGRISSO manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

TAGRISSO Suppliers

A TAGRISSO supplier is an individual or a company that provides TAGRISSO active pharmaceutical ingredient (API) or TAGRISSO finished formulations upon request. The TAGRISSO suppliers may include TAGRISSO API manufacturers, exporters, distributors and traders.

click here to find a list of TAGRISSO suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

TAGRISSO USDMF

A TAGRISSO DMF (Drug Master File) is a document detailing the whole manufacturing process of TAGRISSO active pharmaceutical ingredient (API) in detail. Different forms of TAGRISSO DMFs exist exist since differing nations have different regulations, such as TAGRISSO USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A TAGRISSO DMF submitted to regulatory agencies in the US is known as a USDMF. TAGRISSO USDMF includes data on TAGRISSO's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The TAGRISSO USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of TAGRISSO suppliers with USDMF on PharmaCompass.

TAGRISSO KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a TAGRISSO Drug Master File in Korea (TAGRISSO KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of TAGRISSO. The MFDS reviews the TAGRISSO KDMF as part of the drug registration process and uses the information provided in the TAGRISSO KDMF to evaluate the safety and efficacy of the drug.

After submitting a TAGRISSO KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their TAGRISSO API can apply through the Korea Drug Master File (KDMF).

click here to find a list of TAGRISSO suppliers with KDMF on PharmaCompass.

TAGRISSO WC

A TAGRISSO written confirmation (TAGRISSO WC) is an official document issued by a regulatory agency to a TAGRISSO manufacturer, verifying that the manufacturing facility of a TAGRISSO active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting TAGRISSO APIs or TAGRISSO finished pharmaceutical products to another nation, regulatory agencies frequently require a TAGRISSO WC (written confirmation) as part of the regulatory process.

click here to find a list of TAGRISSO suppliers with Written Confirmation (WC) on PharmaCompass.

TAGRISSO NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing TAGRISSO as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for TAGRISSO API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture TAGRISSO as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain TAGRISSO and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a TAGRISSO NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of TAGRISSO suppliers with NDC on PharmaCompass.

TAGRISSO GMP

TAGRISSO Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of TAGRISSO GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right TAGRISSO GMP manufacturer or TAGRISSO GMP API supplier for your needs.

TAGRISSO CoA

A TAGRISSO CoA (Certificate of Analysis) is a formal document that attests to TAGRISSO's compliance with TAGRISSO specifications and serves as a tool for batch-level quality control.

TAGRISSO CoA mostly includes findings from lab analyses of a specific batch. For each TAGRISSO CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

TAGRISSO may be tested according to a variety of international standards, such as European Pharmacopoeia (TAGRISSO EP), TAGRISSO JP (Japanese Pharmacopeia) and the US Pharmacopoeia (TAGRISSO USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty